RObotic-Assisted Rehabilitation for balance and gait in Stroke patients (ROAR-S): study protocol for a preliminary randomized controlled trial.
Elderly
Falls
Older adults
Rehabilitation
Technology
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
12 Oct 2022
12 Oct 2022
Historique:
received:
14
06
2022
accepted:
03
10
2022
entrez:
12
10
2022
pubmed:
13
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Stroke, the incidence of which increases with age, has a negative impact on motor and cognitive performance, quality of life, and the independence of the person and his or her family, leading to a number of direct and indirect costs. Motor recovery is essential, especially in elderly patients, to enable the patient to be independent in activities of daily living and to prevent falls. Several studies have shown how robotic training associated with physical therapy influenced functional and motor outcomes of walking after stroke by improving endurance and walking strategies. Considering data from previous studies and patients' needs in gait and balance control, we hypothesized that robot-assisted balance treatment associated with physical therapy may be more effective than usual therapy performed by a physical therapist in terms of improving static, dynamic balance and gait, on fatigue and cognitive performance. This is an interventional, single-blinded, preliminary randomized control trial. Twenty-four patients of both sexes will be recruited, evaluated, and treated at the UOC Rehabilitation and Physical Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome from January to December 2022. Patients will be randomized into two groups: the experimental group will perform specific rehabilitation for balance disorder using the Hunova® robotic platform (Movendo Technology srl, Genoa, IT) for 3 times a week, for 4 weeks (12 total sessions), and for 45 min of treatment, in addition to conventional treatment, while the conventional group (GC) will perform only conventional treatment as per daily routine. All patients will undergo clinical and instrumental evaluation at the beginning and end of the 4 weeks of treatment. The study aims to evaluate the improvement in balance, fatigue, quality of life, and motor and cognitive performance after combined conventional and robotic balance treatment with Hunova® (Movendo Technology srl, Genoa, IT) compared with conventional therapy alone. Robotic assessment to identify the most appropriate and individualized rehabilitation treatment may allow reducing disability and improving quality of life in the frail population. This would reduce direct and indirect social costs of care and treatment for the National Health Service and caregivers. ClinicalTrials.gov NCT05280587. Registered on March 15, 2022.
Sections du résumé
BACKGROUND
BACKGROUND
Stroke, the incidence of which increases with age, has a negative impact on motor and cognitive performance, quality of life, and the independence of the person and his or her family, leading to a number of direct and indirect costs. Motor recovery is essential, especially in elderly patients, to enable the patient to be independent in activities of daily living and to prevent falls. Several studies have shown how robotic training associated with physical therapy influenced functional and motor outcomes of walking after stroke by improving endurance and walking strategies. Considering data from previous studies and patients' needs in gait and balance control, we hypothesized that robot-assisted balance treatment associated with physical therapy may be more effective than usual therapy performed by a physical therapist in terms of improving static, dynamic balance and gait, on fatigue and cognitive performance.
METHODS
METHODS
This is an interventional, single-blinded, preliminary randomized control trial. Twenty-four patients of both sexes will be recruited, evaluated, and treated at the UOC Rehabilitation and Physical Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome from January to December 2022. Patients will be randomized into two groups: the experimental group will perform specific rehabilitation for balance disorder using the Hunova® robotic platform (Movendo Technology srl, Genoa, IT) for 3 times a week, for 4 weeks (12 total sessions), and for 45 min of treatment, in addition to conventional treatment, while the conventional group (GC) will perform only conventional treatment as per daily routine. All patients will undergo clinical and instrumental evaluation at the beginning and end of the 4 weeks of treatment.
CONCLUSIONS
CONCLUSIONS
The study aims to evaluate the improvement in balance, fatigue, quality of life, and motor and cognitive performance after combined conventional and robotic balance treatment with Hunova® (Movendo Technology srl, Genoa, IT) compared with conventional therapy alone. Robotic assessment to identify the most appropriate and individualized rehabilitation treatment may allow reducing disability and improving quality of life in the frail population. This would reduce direct and indirect social costs of care and treatment for the National Health Service and caregivers.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05280587. Registered on March 15, 2022.
Identifiants
pubmed: 36224575
doi: 10.1186/s13063-022-06812-w
pii: 10.1186/s13063-022-06812-w
pmc: PMC9558956
doi:
Banques de données
ClinicalTrials.gov
['NCT05280587']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
872Informations de copyright
© 2022. The Author(s).
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Front Neurol. 2020 Nov 19;11:588285
pubmed: 33329334
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Med J Islam Repub Iran. 2012 Feb;26(1):27-30
pubmed: 23483112
Aging Clin Exp Res. 2018 Sep;30(9):1015-1021
pubmed: 29340963
Monaldi Arch Chest Dis. 2012 Sep;78(3):155-9
pubmed: 23614330
Int Psychogeriatr. 2018 Jan;30(1):153-159
pubmed: 28899441
Eur Rev Med Pharmacol Sci. 2016 Nov;20(21):4574-4580
pubmed: 27874938
Int Disabil Stud. 1988;10(2):61-3
pubmed: 3403500
Front Psychol. 2017 Apr 12;8:557
pubmed: 28446889
NeuroRehabilitation. 2017;41(4):775-782
pubmed: 28946585
Aging Clin Exp Res. 2002 Apr;14(2):117-31
pubmed: 12092785
N Engl J Med. 1975 Nov 6;293(19):954-6
pubmed: 1178004
J Gerontol A Biol Sci Med Sci. 2010 Apr;65(4):369-76
pubmed: 20064836
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
J Bras Pneumol. 2011 Jan-Feb;37(1):110-7
pubmed: 21390439
Neurol Sci. 2020 May;41(5):1251-1257
pubmed: 31919697
BMC Neurol. 2012 Nov 14;12:137
pubmed: 23150894
Neurology. 2016 Sep 13;87(11):1085-92
pubmed: 27521436
Neurol Sci. 2016 May;37(5):673-9
pubmed: 26728268
J Clin Med. 2022 Aug 31;11(17):
pubmed: 36079092
J Am Med Dir Assoc. 2019 May;20(5):564-568
pubmed: 30852165
Front Hum Neurosci. 2016 Sep 13;10:442
pubmed: 27679565
J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):89-96
pubmed: 20861145
Qual Life Res. 2012 Aug;21(6):925-44
pubmed: 22012025
NeuroRehabilitation. 2019;45(2):201-212
pubmed: 31498139
Lancet Neurol. 2009 Aug;8(8):741-54
pubmed: 19608100
Scand J Rehabil Med. 1995 Mar;27(1):27-36
pubmed: 7792547
N Engl J Med. 1983 Jan 27;308(4):173-80
pubmed: 6294517
Telemed J E Health. 2012 Jan-Feb;18(1):54-9
pubmed: 22082108
Cochrane Database Syst Rev. 2020 Oct 22;10:CD006185
pubmed: 33091160
Neurol Sci. 2021 Nov;42(11):4615-4621
pubmed: 33661481
Eur Neurol. 2012;67(6):377-84
pubmed: 22614741
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Arch Phys Med Rehabil. 2007 Oct;88(10):1314-9
pubmed: 17908575
Stroke. 1995 Jun;26(6):982-9
pubmed: 7762050
Acta Neurol Scand. 2016 May;133(5):346-54
pubmed: 26234280
Acta Neurol Belg. 2020 Aug;120(4):783-790
pubmed: 32166723
Lancet. 2014 Jan 18;383(9913):245-54
pubmed: 24449944
Gait Posture. 2015 Mar;41(3):780-5
pubmed: 25770078